Evidence map›Paper›PMID 27429842›Full record

ArticleAmerican journal of cancer research2016

CASZ1 is a novel promoter of metastasis in ovarian cancer.

Yi-Ying Wu, Chia-Lin Chang, Yuan-Jhe Chuang, Jia-En Wu, Chia-Hao Tung, Yeong-Chang Chen, Yuh-Ling Chen, Tse-Ming Hong, Keng-Fu Hsu

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. CASZ1 Is Essential for Skin Epidermal Terminal Differentiation.The Journal of investigative dermatology · 2024
    Article
  3. Review
  4. Biomedicines · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. CASZ1b is a novel transcriptional corepressor of mineralocorticoid receptor.Hypertension research : official journal of the Japanese Society of Hypertension · 2021
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yi-Ying WuGraduate Institute of Clinical Medicine, College of Medicine, National Cheng Kung University Tainan, Taiwan.
Chia-Lin ChangGraduate Institute of Clinical Medicine, College of Medicine, National Cheng Kung University Tainan, Taiwan.
Yuan-Jhe ChuangGraduate Institute of Clinical Medicine, College of Medicine, National Cheng Kung University Tainan, Taiwan.
Jia-En WuInstitute of Basic Medical Sciences, College of Medicine, National Cheng Kung University Tainan, Taiwan.
Chia-Hao TungInstitute of Basic Medical Sciences, College of Medicine, National Cheng Kung University Tainan, Taiwan.
Yeong-Chang ChenDepartment of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan, Taiwan.
Yuh-Ling ChenInstitute of Oral Medicine, College of Medicine, National Cheng Kung University Tainan, Taiwan.
Tse-Ming HongGraduate Institute of Clinical Medicine, College of Medicine, National Cheng Kung University Tainan, Taiwan.
Keng-Fu HsuGraduate Institute of Clinical Medicine, College of Medicine, National Cheng Kung UniversityTainan, Taiwan; Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung UniversityTainan, Taiwan.
National Cheng Kung University · TWNational Cheng Kung University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) carries the highest mortality rate of all gynecologic malignancies. This high mortality rate is attributed to the fact that most cases of ovarian cancer are detected at late stages when metastases are already present. Through microarray analysis, we previously demonstrated that castor zinc finger 1 (CASZ1) is up-regulated in EOC cells. In contrast to its role in EOC, CASZ1 functions a tumor suppressor in neuroblastoma. Human CASZ1 is predominantly expressed in 2 alternatively spliced isoforms: CASZ1a and CASZ1b. In the present study, we investigated the role of CASZ1 in ovarian cancer cell migration and invasion and assessed the value of CASZ1 expression as a prognostic indicator of metastasis in human ovarian cancer. We used a lentivirus expressing CASZ1-shRNA and a plasmid expressing CASZ1 from a CMV promoter to knockdown and overexpress CASZ1, respectively, in the MCAS, RMUG-S, TOV21G, and A2780(CP70) ovarian cancer cell lines. mRNA expression levels in tumor tissues and cell lines were measured using quantitative real-time PCR, and CASZ1 protein expression in EOC and paired metastatic tumor tissues was analyzed using immunohistochemistry. We found that CASZ1 was highly expressed in EOC tissues and ovarian cancer cell lines and that CASZ1 knockdown suppressed cell migration and invasion in EOC cells. CASZ1a and CASZ1b exerted similar effects on cell migration and invasion in EOC cells. In addition, CASZ1 promoted the epithelial-mesenchymal transition in EOC cells, and CASZ1 knockdown suppressed cancer metastasis in vivo. Furthermore, CASZ1 protein levels were elevated in human metastatic ovarian tumor tissues. Together, these results indicate that CASZ1 is a novel promoter of EOC metastasis and is highly up-regulated in metastatic EOC tumors.

Indexed as

cancer metastasisCASZ1epithelial ovarian cancer

Identifiers

PMID27429842
PMCPMC4937731
OpenAlexW2506160279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.